Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 7:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,281 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cancer, Head and Neck Clear all
Completed Phase 1 Interventional

Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT02035527
View directory record Official record
Conditions
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Oral Cavity Squamous Cell Carcinoma, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer, Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions
sorafenib tosylate, cisplatin, docetaxel, Correlative Studies
Drug · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Sep 18, 2026, 7:45 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors

NCT07749586
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
ARV-6723, Pembrolizumab, SOC
Drug
Lead sponsor
Arvinas Inc.
Industry
Eligibility
18 Years and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
3
States / cities
Huntersville, North Carolina • San Antonio, Texas • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 18, 2026, 7:45 PM EDT
Recruiting Phase 1 Interventional

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

NCT06022029
View directory record Official record
Conditions
Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin, Mantle Cell Lymphoma, Bladder Cancer, Uveal Melanoma, Recurrent, Cervix Cancer, Carcinoma in Situ, Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Cancer, Tumor, Solid, Tumor Recurrence
Interventions
ONM-501, Cemiplimab
Drug
Lead sponsor
OncoNano Medicine, Inc.
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
9
States / cities
Los Angeles, California • Tamarac, Florida • Canton, Ohio + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 18, 2026, 7:45 PM EDT
Terminated Phase 1 Interventional

A Safety Study of SGN-CD47M in Patients With Solid Tumors

NCT03957096
View directory record Official record
Conditions
Soft Tissue Sarcoma, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Carcinoma, Breast Carcinoma, Ovarian Carcinoma, Exocrine Pancreatic Carcinoma, Gastric Carcinoma, Melanoma
Interventions
SGN-CD47M
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
Cleveland, Ohio • Portland, Oregon • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Sep 18, 2026, 7:45 PM EDT
Completed Phase 3 Interventional

Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer

NCT00090337
View directory record Official record
Conditions
Head and Neck Cancer, Pain
Interventions
acupuncture therapy, standard follow-up care
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2013 · Synced Sep 18, 2026, 7:45 PM EDT
Recruiting Phase 1 Interventional

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

NCT05005403
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Micro Satellite Stable Colorectal Cancer, Gastric/Esophageal Cancer, High-Grade Serous Ovarian Cancer, Pancreatic Cancer, Triple Negative Breast Cancer
Interventions
Azirkitug, Budigalimab, Bevacizumab, Telisotuzumab Adizutecan
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
694 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
20
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 18, 2026, 7:45 PM EDT
Recruiting No phase listed Observational

Targeted Therapy to Increase RAI Uptake in Metastatic DTC

NCT05024929
View directory record Official record
Conditions
Papillary Thyroid Cancer, Pediatric Cancer, Differentiated Thyroid Cancer
Interventions
Whole body scan
Procedure
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
0 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2033
U.S. locations
8
States / cities
San Francisco, California • Atlanta, Georgia • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 18, 2026, 7:45 PM EDT
Completed Not applicable Interventional

Feasibility Study of Dynasplint to Prevent Trismus in Head and Neck Cancer

NCT01649583
View directory record Official record
Conditions
Trismus, Head and Neck Cancer
Interventions
Jaw Dynasplint System
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Sep 18, 2026, 7:45 PM EDT
Completed Phase 1 Interventional

Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors

NCT00014456
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Carcinoma of Unknown Primary, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma
Interventions
filgrastim, docetaxel, gemcitabine hydrochloride
Biological · Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 27, 2013 · Synced Sep 18, 2026, 7:45 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

NCT06295731
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions
INBRX-106, Pembrolizumab
Drug
Lead sponsor
Inhibrx Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
25
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 18, 2026, 7:45 PM EDT
Recruiting Not applicable Interventional

Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Diagnosing Osteoradionecrosis in Patients With Head and Neck Cancer That Is Primary, Has Come Back, or Has Spread to Other Places in the Body

NCT03145077
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Questionnaire Administration
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 18, 2026, 7:45 PM EDT
Completed Phase 1 Interventional

Simultaneous Integrated Boost (SIB) in Esophageal Cancer

NCT01102088
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Radiation Therapy
Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Sep 18, 2026, 7:45 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Cognitive Outcomes After Brain Substructure-informed Radiation Planning in Pediatric Patients

NCT05658731
View directory record Official record
Conditions
Brain Tumor, Head and Neck Cancer
Interventions
substructure informed planning, Neurocognitive Testing, MRI
Radiation · Other · Diagnostic Test
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
1 Year to 26 Years
Enrollment
338 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2035
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 18, 2026, 7:45 PM EDT
Completed Phase 2 Interventional Results available

Salivary Gland Surgery Before Radiation Therapy in Preventing Radiation-Caused Xerostomia in Patients With Head and Neck Cancer

NCT00068237
View directory record Official record
Conditions
Head and Neck Cancer, Radiation Toxicity, Xerostomia
Interventions
salivary gland transfer, Post-operative radiation therapy
Procedure · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
9
States / cities
Gainesville, Florida • Miami, Florida • Springfield, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Sep 18, 2026, 7:45 PM EDT
Recruiting Not applicable Interventional

Physiologic MR Imaging of Salivary Gland Tumors

NCT04452162
View directory record Official record
Conditions
Salivary Gland Tumor
Interventions
MRI
Diagnostic Test
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 18, 2026, 7:45 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

NCT05902988
View directory record Official record
Conditions
Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary, Squamous Non-small-cell Lung Cancer, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Ovarian Carcinosarcoma, Uterine Carcinosarcoma, Uterine Serous Carcinoma, Endometrium Cancer, Chromosomal Instability
Interventions
VLS-1488
Drug
Lead sponsor
Volastra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
14
States / cities
Los Angeles, California • Newport Beach, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 18, 2026, 7:45 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

APG-115 in Salivary Gland Cancer Trial

NCT03781986
View directory record Official record
Conditions
Malignant Salivary Gland Cancer, Salivary Gland Cancer
Interventions
APG-115, Carboplatin
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
3
States / cities
Tampa, Florida • Chicago, Illinois • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 18, 2026, 7:45 PM EDT
Recruiting Not applicable Interventional

TRAIL Study: Feasibility and Pilot

NCT06220656
View directory record Official record
Conditions
Thyroid Nodule, Thyroid Neoplasms, Thyroid Cancer
Interventions
Biopsy, Active Monitoring
Procedure
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 18, 2026, 7:45 PM EDT
Terminated Not applicable Interventional

EMST and Swallowing in Long-Term Survivors of HNCA

NCT03975465
View directory record Official record
Conditions
Head and Neck Neoplasms, Deglutition Disorders
Interventions
Expiratory Muscle Strength Training, Pharyngeal Muscle Strengthening Exercises
Behavioral
Lead sponsor
University of Wisconsin, Milwaukee
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Sep 18, 2026, 7:45 PM EDT
Completed Phase 2 Interventional Results available

A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis

NCT00565721
View directory record Official record
Conditions
High-grade Glioma, Lung Cancer, Head & Neck Cancer, Sarcoma, Melanoma
Interventions
Fluciclatide Injection - (AH111585 (F18))
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 17, 2014 · Synced Sep 18, 2026, 7:45 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Geriatric Assessment and Management for Older Adults Undergoing Chemotherapy and Radiation Therapy for Head and Neck Cancer and Their Family Caregivers

NCT07225855
View directory record Official record
Conditions
Localized Head and Neck Carcinoma
Interventions
Best Practice, Electronic Health Record Review, Health Communication, Interview, Office Visit, Practical Geriatric Assessment, Questionnaire Administration, Referral, Supportive Care
Other · Behavioral
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 18, 2026, 7:45 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer

NCT00002515
View directory record Official record
Conditions
Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Head and Neck Cancer, Kidney Cancer, Liver Cancer, Lymphoma, Neuroblastoma, Ovarian Cancer, Retinoblastoma, Sarcoma, Testicular Germ Cell Tumor
Interventions
filgrastim, carboplatin, thiotepa, topotecan hydrochloride, autologous bone marrow transplantation, bone marrow ablation with stem cell support, in vitro-treated bone marrow transplantation
Biological · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2013 · Synced Sep 18, 2026, 7:45 PM EDT
Completed Phase 1 Interventional

Gabapentin, Methadone Hydrochloride, and Oxycodone Hydrochloride in Improving Quality of Life in Patients With Stage II-IV Head and Neck Cancer During Chemoradiation

NCT02531906
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Pain, Stomatitis
Interventions
Gabapentin, Methadone Hydrochloride, Oxycodone Hydrochloride, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2022 · Synced Sep 18, 2026, 7:45 PM EDT
Terminated Phase 1 Interventional

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

NCT04244552
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Ovarian Cancer, Non-Small Cell Lung Cancer, Acral Lentiginous Melanoma, Head and Neck Squamous Cell Carcinoma, Hepatocellular Carcinoma, Esophageal Squamous Cell Carcinoma, Urothelial Carcinoma, DMMR Colorectal Cancer, MSI-H Colorectal Cancer, Melanoma, Platinum-Resistant Primary Peritoneal Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer
Interventions
ATRC-101, Pembrolizumab, Pegylated liposomal doxorubicin (PLD)
Biological · Drug
Lead sponsor
Atreca, Inc.
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
19
States / cities
Phoenix, Arizona • Tucson, Arizona • Duarte, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Sep 18, 2026, 7:45 PM EDT